• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2018 and Operational Progress

    Gabrielle Lakusta
    Jun. 05, 2018 08:59AM PST
    Pharmaceutical Investing

    Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM) today reports its financial results for the first quarter ended 30 April 2018 and provides an update on operational progress. As quoted in the press release: Mr Glyn Edwards, Chief Executive Officer of Summit, commented: “The strength of the interim data from our PhaseOut DMD trial has bolstered our belief that ezutromid …

    Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM) today reports its financial results for the first quarter ended 30 April 2018 and provides an update on operational progress.

    As quoted in the press release:

    Mr Glyn Edwards, Chief Executive Officer of Summit, commented: “The strength of the interim data from our PhaseOut DMD trial has bolstered our belief that ezutromid could become a new standard of care for all patients with Duchenne muscular dystrophy (‘DMD’). These interim data showed a statistically significant and meaningful reduction in both muscle damage and muscle inflammation after just 24 weeks of treatment. Should these changes be sustained after 48 weeks of treatment, we believe we will be positioned to pursue an accelerated path to regulatory approval for ezutromid. We look forward to the full trial results in the third quarter of this year.”

    Click here to read the full press release.

    pharmaceutical investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Medical pills branded with Canadian flag.

    Canadian Pharma Stocks: 5 Biggest Companies

    Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×